Detecting and Targetting Oncogenic Fusion Proteins in the Genomic Era

Overview

Journal Biol Cell

Specialty Cell Biology

Date 2015 Jan 30

PMID 25631473

Citations 20

Authors

Monika A Davare

Cristina E Tognon

Affiliations

Soon will be listed here.

Abstract

The advent of widespread cancer genome sequencing has accelerated our understanding of the molecular aberrations underlying malignant disease at an unprecedented rate. Coupling the large number of bioinformatic methods developed to locate genomic breakpoints with increased sequence read length and a deeper understanding of coding region function has enabled rapid identification of novel actionable oncogenic fusion genes. Using examples of kinase fusions found in liquid and solid tumours, this review highlights major concepts that have arisen in our understanding of cancer pathogenesis through the study of fusion proteins. We provide an overview of recently developed methods to identify potential fusion proteins from next-generation sequencing data, describe the validation of their oncogenic potential and discuss the role of targetted therapies in treating cancers driven by fusion oncoproteins.

Citing Articles

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain.

Jones K, Keddy C, Jenkins C, Nicholson K, Shinde U, Davare M Sci Rep. 2024; 14(1):22191.

PMID: 39333184 PMC: 11437283. DOI: 10.1038/s41598-024-71687-7.

Current Targeted Therapy for Metastatic Colorectal Cancer.

Ohishi T, Kaneko M, Yoshida Y, Takashima A, Kato Y, Kawada M Int J Mol Sci. 2023; 24(2).

PMID: 36675216 PMC: 9864602. DOI: 10.3390/ijms24021702.

Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.

Carballo E, Pham T, Turashvili G, Hanley K, Starbuck K, Meisel J Gynecol Oncol Rep. 2022; 43:101062.

PMID: 36032811 PMC: 9403501. DOI: 10.1016/j.gore.2022.101062.

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.

Iyer S, Odintsov I, Schoenfeld A, Siau E, Mattar M, de Stanchina E Mol Cancer Res. 2022; 20(5):722-734.

PMID: 35149545 PMC: 9081178. DOI: 10.1158/1541-7786.MCR-22-0025.

Functional characterization of NPM1-TYK2 fusion oncogene.

Kuravi S, Baker R, Mushtaq M, Saadi I, Lin T, Vivian C NPJ Precis Oncol. 2022; 6(1):3.

PMID: 35042970 PMC: 8766497. DOI: 10.1038/s41698-021-00246-4.

References

Jones D, Hutter B, Jager N, Korshunov A, Kool M, Warnatz H . Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013; 45(8):927-32. PMC: 3951336. DOI: 10.1038/ng.2682. View

Yorukoglu D, Hach F, Swanson L, Collins C, Birol I, Sahinalp S . Dissect: detection and characterization of novel structural alterations in transcribed sequences. Bioinformatics. 2012; 28(12):i179-87. PMC: 3371846. DOI: 10.1093/bioinformatics/bts214. View

Kralik J, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H . Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011; 6:19. PMC: 3063188. DOI: 10.1186/1746-1596-6-19. View

Sun R, Love M, Zemojtel T, Emde A, Chung H, Vingron M . Breakpointer: using local mapping artifacts to support sequence breakpoint discovery from single-end reads. Bioinformatics. 2012; 28(7):1024-5. DOI: 10.1093/bioinformatics/bts064. View

Birchmeier C, Sharma S, Wigler M . Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987; 84(24):9270-4. PMC: 299735. DOI: 10.1073/pnas.84.24.9270. View

Huang E, Reichardt L . Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001; 24:677-736. PMC: 2758233. DOI: 10.1146/annurev.neuro.24.1.677. View

Thiele C, Li Z, McKee A . On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009; 15(19):5962-7. PMC: 2756331. DOI: 10.1158/1078-0432.CCR-08-0651. View

Debelenko L, Arthur D, Pack S, Helman L, Schrump D, Tsokos M . Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest. 2003; 83(9):1255-65. DOI: 10.1097/01.lab.0000088856.49388.ea. View

McPherson A, Wu C, Hajirasouliha I, Hormozdiari F, Hach F, Lapuk A . Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data. Bioinformatics. 2011; 27(11):1481-8. DOI: 10.1093/bioinformatics/btr184. View

10.

Piazza R, Pirola A, Spinelli R, Valletta S, Redaelli S, Magistroni V . FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Res. 2012; 40(16):e123. PMC: 3439881. DOI: 10.1093/nar/gks394. View

11.

Nakagawara A . Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001; 169(2):107-14. DOI: 10.1016/s0304-3835(01)00530-4. View

12.

Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R . KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012; 7(2):e31323. PMC: 3275577. DOI: 10.1371/journal.pone.0031323. View

13.

Ardini E, Bosotti R, Borgia A, De Ponti C, Somaschini A, Cammarota R . The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014; 8(8):1495-507. PMC: 5528583. DOI: 10.1016/j.molonc.2014.06.001. View

14.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

15.

Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H . Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003; 37(1):58-71. DOI: 10.1002/gcc.10207. View

16.

Fehr A, Loning T, Stenman G . Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2011; 35(10):1600-2. DOI: 10.1097/PAS.0b013e31822832c7. View

17.

Liu H, Westergard T, Cashen A, Piwnica-Worms D, Kunkle L, Vij R . Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell. 2014; 25(4):530-42. PMC: 4097146. DOI: 10.1016/j.ccr.2014.03.008. View

18.

Zabriskie M, Eide C, Tantravahi S, Vellore N, Estrada J, Nicolini F . BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014; 26(3):428-442. PMC: 4160372. DOI: 10.1016/j.ccr.2014.07.006. View

19.

Kim J, Wu L, Zhao J, Jin H, Yu J . TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene. 2013; 33(44):5183-92. PMC: 4009393. DOI: 10.1038/onc.2013.461. View

20.

Birch A, Arcand S, Oros K, Rahimi K, Watters A, Provencher D . Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One. 2011; 6(12):e28250. PMC: 3232202. DOI: 10.1371/journal.pone.0028250. View